TY - JOUR
T1 - Quinpramine - A promising compound for treating immune-mediated demyelination of the nervous system
AU - Meyer Zu Hörste, Gerd
AU - Mausberg, Anne K.
AU - Korth, Carsten
AU - Stüve, Olaf
AU - Kieseier, Bernd C.
PY - 2010/6
Y1 - 2010/6
N2 - Multiple sclerosis (MS) is a chronic demyelinating autoimmune disease of the central nervous system. Different therapeutic options are available, but all require parenteral application and some expose patients to potentially lethal adverse effects. The response to treatment remains variable and often incomplete. Thus, the search for novel therapeutic agents is ongoing and relevant. The chimeric compound quinpramine-generated from its precursor substances Imipramine and quinacrine-has recently demonstrated clinical efficacy in experimental autoimmune encephalomyelitis (EAE), an animal model for MS. Mechanistic considerations and recent experimental data suggest that intracellular redistribution of antigen-presenting molecules and cholesterol-rich membrane domains may account for the clinical efficacy of this drug. This article summarizes available treatment options in MS and explains why the candidate compound quinpramine may transfer from bench to bedside in the near future.
AB - Multiple sclerosis (MS) is a chronic demyelinating autoimmune disease of the central nervous system. Different therapeutic options are available, but all require parenteral application and some expose patients to potentially lethal adverse effects. The response to treatment remains variable and often incomplete. Thus, the search for novel therapeutic agents is ongoing and relevant. The chimeric compound quinpramine-generated from its precursor substances Imipramine and quinacrine-has recently demonstrated clinical efficacy in experimental autoimmune encephalomyelitis (EAE), an animal model for MS. Mechanistic considerations and recent experimental data suggest that intracellular redistribution of antigen-presenting molecules and cholesterol-rich membrane domains may account for the clinical efficacy of this drug. This article summarizes available treatment options in MS and explains why the candidate compound quinpramine may transfer from bench to bedside in the near future.
UR - http://www.scopus.com/inward/record.url?scp=77955915877&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955915877&partnerID=8YFLogxK
U2 - 10.1358/dnp.2010.23.5.1447850
DO - 10.1358/dnp.2010.23.5.1447850
M3 - Review article
C2 - 20603652
AN - SCOPUS:77955915877
SN - 0214-0934
VL - 23
SP - 287
EP - 294
JO - Drug News and Perspectives
JF - Drug News and Perspectives
IS - 5
ER -